Molnar Miklos Zsolt, Fornadi Katalin, Shapiro Colin M
1st Department of Internal Medicine, Fresenius Medical Care Dialysis Center, Institute of Behavioral Sciences, Semmelweis University, Budapest, Hungary.
Drugs Today (Barc). 2006 Sep;42(9):587-98. doi: 10.1358/dot.2006.42.9.996568.
In this paper we discuss therapy with ropinirole (known as adartrel in the United Kingdom) in patients with restless legs syndrome. Restless legs syndrome is characterized by an urge to move the legs, uncomfortable sensations in the legs and worsening of these symptoms during rest with at least temporary relief brought on by activity. Current recommendations suggest dopaminergic therapy (levodopa or dopamine receptor agonists like ropinirole) as the first-line treatment for restless legs syndrome. Based on the results of randomized, placebo-controlled, double-blind trials, we conclude that ropinirole is effective in reducing symptoms of restless legs syndrome in the general population. Ropinirole has no serious or common side effects that would limit its use significantly. Rebound and augmentation problems are relatively rarely seen with ropinirole, although properly designed comparative trials are still needed to address this question. It must be noted, however, that most published studies with ropinirole compare this drug with placebo. Very few studies have compared ropinirole with other drugs (L-dopa, gabapentin, opioids, benzodiazepines, other dopaminergic agents and selegiline hydrochloride). No cost-effectiveness trial has been published yet. Treatment of restless legs syndrome with ropinirole shows it to be effective, well-tolerated and safe and it can be used in restless legs syndrome in general.
在本文中，我们探讨了罗匹尼罗（在英国称为阿达尔特）用于治疗不宁腿综合征患者的情况。不宁腿综合征的特征是腿部有活动冲动、腿部有不适感，且这些症状在休息时加重，活动后至少可暂时缓解。目前的建议是将多巴胺能疗法（左旋多巴或多巴胺受体激动剂如罗匹尼罗）作为不宁腿综合征的一线治疗方法。基于随机、安慰剂对照、双盲试验的结果，我们得出结论，罗匹尼罗在减轻普通人群不宁腿综合征症状方面是有效的。罗匹尼罗没有严重或常见的副作用会显著限制其使用。罗匹尼罗相对很少出现反跳和增敏问题，不过仍需要设计合理的对比试验来解决这个问题。然而，必须指出的是，大多数已发表的关于罗匹尼罗的研究将这种药物与安慰剂进行比较。很少有研究将罗匹尼罗与其他药物（左旋多巴、加巴喷丁、阿片类药物、苯二氮䓬类药物、其他多巴胺能药物和盐酸司来吉兰）进行比较。尚未发表成本效益试验。用罗匹尼罗治疗不宁腿综合征显示其有效、耐受性良好且安全，一般可用于不宁腿综合征。
